EN | UA
EN | UA

Help Support

Back

Nitrogen-based bisphosphonates efficiently reduced the mortality risks among osteoporosis patients

Nitrogen-based bisphosphonates efficiently reduced the mortality risks among osteoporosis patients Nitrogen-based bisphosphonates efficiently reduced the mortality risks among osteoporosis patients
Nitrogen-based bisphosphonates efficiently reduced the mortality risks among osteoporosis patients Nitrogen-based bisphosphonates efficiently reduced the mortality risks among osteoporosis patients

What's new?

As compared to non-nitrogen bisphosphonate users, nitrogen bisphosphonate users show ~ 50% better survival rate.

Osteoporotic patients exhibited better improvements with the treatment comprising nitrogen bisphosphonates, evident from an observational study of 6120 participants aged 50+ published in the Journal of Osteoporosis International. The aim of this analysis was to assess the relationship between various classes of BP and mortality risk among people with or without a fracture.


Users of different BPs resembled with non-users by propensity score (gender, age, fragility fracture status, co-morbidities) and with the time to initiating BP medicine from the population-based Canadian Multicentre Osteoporosis Study. Mortality risk between BP users and matched non-users were evaluated by applying the multivariable Cox proportional hazards models.


The BP group comprised 308 men and 2048 women and non-users group comprised 1794 men and 1970 women. The association between mortality risk and BP was assessed in three different 1:1 propensity score-matched cohorts (Etidronate, Risedronate, and Alendronate) of BP users and non-users. Further, the rates of mortality were lower and within patients used Nitrogen BP (n-BP) (Alendronate and Risedronate) as compared to non-n-BP (Etidronate). The n-BP also exhibited a better survival as compared to the non-n-BP. As per these findings, as compared to no treatment, nitrogen bisphosphonates exhibited better survival and lower mortality rates.  

Source:

Osteoporosis International

Article:

Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.

Authors:

D. Bliuc et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: